GlaxoSmithKline's corporate venturing unit backs the US-based women's reproductive health company, joining Merck Serono Ventures, Kleiner Perkins Caufield and Byers and TPG Biotech in the syndicate.
SR One, the corporate venturing unit of pharmaceutical company GlaxoSmithKline, has helped Auxogyn, a US-based women’s reproductive health company, raise $18m.
SR One led the series B round, and was joined by prior investors in Auxogyn, Merck Serono Ventures, the corporate venturing unit of the eponymous Germany-based pharmaceuticals group, as well as venture firms Kleiner Perkins Caufield and Byers and TPG Biotech.
Simeon J. George, partner at SR One, and Nilesh Kumar, director of Merck Serono Ventures, have joined Auxogyn’s…
